{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-23-000029","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.201178+00:00","generated_at":"2026-06-09T01:24:55.070945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Regeneron Q3 revenue $3.36B (+15%); GAAP EPS $8.89, non-GAAP EPS $11.59; EYLEA HD launch begins","bullets":["Revenue $3.363B (+15% YoY); GAAP EPS $8.89, non-GAAP EPS $11.59.","EYLEA HD launched post-FDA approval, generated $43M U.S. net sales in Q3.","Dupixent global net sales (Sanofi) $3.10B (+33% YoY); Libtayo global net sales $232M (+62%).","FDA accepted priority reviews for odronextamab in FL/DLBCL and Dupixent in pediatric EoE; CRL for Dupixent in CSU.","CFO Robert Landry to retire Feb 2024; Christopher Fenimore to succeed."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-23-000029","json":"https://secwatch.observer/filing/0001804220-23-000029.json","markdown":"https://secwatch.observer/filing/0001804220-23-000029.md","text":"https://secwatch.observer/filing/0001804220-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/0001804220-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/regn-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:24:55.070945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e673df7729dfed311855cae2a80fd3fac17cb023","claim":"REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2023 results: revenue $3,363, net income $1,008, EPS $8.89.","evidence_excerpt":"to our portfolio through the recent acquisition of Decibel Therapeutics.\" Financial Highlights ($ in millions, except per share data) Q3 2023 Q3 2022 % Change Total revenues $ 3,363 $ 2,936 15 % GAAP net income $ 1,008 $ 1,316 (23 %) GAAP net income per share - diluted $ 8.89 $ 11.66 (24 %) Non-GAAP net income (a) $ 1,329 $ 1,270 5 % Non-GAAP net income per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/0001804220-23-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$3,363"},{"label":"Net income","value":"$1,008"},{"label":"EPS","value":"$8.89"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}